These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35588345)

  • 1. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
    Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
    Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
    Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
    Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
    Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
    [No Abstract]   [Full Text] [Related]  

  • 6. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
    Okunlola FO; Olotu FA; Soliman MES
    J Biomol Struct Dyn; 2022; 40(21):10878-10886. PubMed ID: 34463214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
    Teng QX; Lei ZN; Wang JQ; Yang Y; Wu ZX; Acharekar ND; Zhang W; Yoganathan S; Pan Y; Wurpel J; Chen ZS; Fang S
    Drug Resist Updat; 2024 Mar; 73():101028. PubMed ID: 38340425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
    Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E
    Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [
    Bowden GD; Stotz S; Kinzler J; Geibel C; Lämmerhofer M; Pichler BJ; Maurer A
    J Med Chem; 2021 Nov; 64(21):15690-15701. PubMed ID: 34672571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
    Wang Q; Zhang J
    Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
    Ding X; Zhu Z; Lapek J; McMillan EA; Zhang A; Chung CY; Dubbury S; Lapira J; Firdaus S; Kang X; Gao J; Oyer J; Chionis J; Rollins RA; Li L; Niessen S; Bagrodia S; Zhang L; VanArsdale T
    Sci Rep; 2022 Jul; 12(1):12501. PubMed ID: 35864202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
    Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
    J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib.
    Challa S; Kraus WL
    Cell Chem Biol; 2022 Feb; 29(2):171-173. PubMed ID: 35180430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.